## Amanda R Moore

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9031340/publications.pdf

Version: 2024-02-01

933447 1372567 1,201 9 10 10 citations h-index g-index papers 10 10 10 2310 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Combined Inhibition of $\widehat{\text{Gl}}\pm q$ and MEK Enhances Therapeutic Efficacy in Uveal Melanoma. Clinical Cancer Research, 2021, 27, 1476-1490.	7.0	29
2	Direct evidence that the GPCR CysLTR2 mutant causative of uveal melanoma is constitutively active with highly biased signaling. Journal of Biological Chemistry, 2021, 296, 100163.	3.4	22
3	ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma. Nature, 2021, 594, 418-423.	27.8	64
4	The promise and peril of KRAS G12C inhibitors. Cancer Cell, 2021, 39, 1059-1061.	16.8	10
5	RAS-targeted therapies: is the undruggable drugged?. Nature Reviews Drug Discovery, 2020, 19, 533-552.	46.4	569
6	Spliceosomal disruption of the non-canonical BAF complex in cancer. Nature, 2019, 574, 432-436.	27.8	163
7	GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal Melanoma. Cell Reports, 2018, 22, 2455-2468.	6.4	75
8	A Tmprss2-CreERT2 Knock-In Mouse Model for Cancer Genetic Studies on Prostate and Colon. PLoS ONE, 2016, 11, e0161084.	2.5	18
9	Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma. Nature Genetics, 2016, 48, 675-680.	21.4	236